WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced positive outcomes from a Phase 2 study evaluating ...

Palvella Therapeutics (PVLA) announced results from the Phase 2 study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth ...